Dyschromia
Therapeutics: Introduction
Dyschromia refers to a condition
marked by any irregular discoloration on the skin, hair or nails, which can
present as single or multiple light or dark patches on the skin. A large part
of the dyschromia treatment market is saturated and highly generalized. There
is an unmet need for more efficacious and safer treatment options, as the available
treatments are associated with poor efficacy, low patient compliance, and
problematic safety profiles. For instance, Sirona Biochem Corp.’s TFC-1067
demonstrates superior efficacy to hydroquinone, the gold standard, for the
treatment of dyschromia. At present, hydroquinone is the gold standard
treatment for skin lightening, despite known toxicity, which is an ongoing
concern for the FDA and the dermatology community.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78970
Key Drivers and
Restraints of Global Dyschromia Therapeutics Market
·
Increase in awareness about skin issues is boosting the demand for
dyschromia treatment. Patients are now more pro-active about their health and
are willing to seek physician's advice at an early stage. Increase in awareness
about the importance of personal appearance and personality development is
another major factor driving the global dyschromia treatment market. In a study
conducted by Center for Dermatology Research, around 80% of the participants in
the U.S. were diagnosed with one or more pigmentation disorders. About 47.3% of
the patients admitted to feeling self-conscious about their skin to some
degree, 21.8% felt others focused on their skin, 32.7% felt unattractive
because of their skin, 32.7% tried to hide their pigmentation, and 23.6% felt
their skin affected their activities.
·
Adoption of laser-based devices has been rising due to the wide utility
of laser devices. Applications include skin photo damage, hyperpigmentation and
hypopigmentation, removal of unwanted hair, acnes, wrinkles, tattoo removal,
facial vein removal, and body contouring. Cost-effectiveness and versatility of
laser devices are also major factors driving the adoption and usage of laser
procedures in the dyschromia treatment market.
Request COVID Analysis on Dyschromia
Therapeutics Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78970
·
Dyschromia adversely impacts a person's quality of life. Increase in
disposable income of the people has led to an improvement in the standard of
living in developed and emerging economies of the world. Additionally, rise in
pigmentation disorders across age-groups and increase in expenditure on
personal care are driving the demand for dyschromia treatment.
North America to
Lead Global Dyschromia Therapeutics Market
·
In terms of region, the global
dyschromia therapeutics market can be segmented into North America, Europe,
Asia Pacific, Latin America, and Middle East & Africa. North America and
Europe are likely to account for major share of the global dyschromia
therapeutics market during the forecast period, owing to developed health care
infrastructure, large patient population, and increase in technological developments
in these regions.
Request Customization on Dyschromia Therapeutics Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=78970
Key Players
Operating in Global Dyschromia Therapeutics Market
·
The global dyschromia therapeutics market is fragmented, with the
presence of less number of small-scale companies in drug development. The
global dyschromia treatment market is built on the principle of new product
innovation. Major market players invest significantly in research and
development to improve the effectiveness of products, such as skin whitening
cosmetics, chemical peels in combination with topicals, and multi-utility
pigmentation skin care products.
·
The treatment landscape for dyschromia has been traditionally dominated
by generalized topical therapies such as hydroquinone
·
Research in dyschromia has led to the development of topical drugs and
phototherapy, with the ability to target specific mediators involved in
dyschromia. Unmet needs in dyschromia therapeutics are creating
significant opportunities for investors. Investment in R&D of
cost-effective solutions is a focus area of major companies. This is expected
to boost the global dyschromia therapeutics market in the next few years.
Pre Book Dyschromia
Therapeutics Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=78970<ype=S
Leading companies
operating in the global dyschromia therapeutics market are:
·
Bayer AG
·
ALLERGAN (AbbVie Inc.)
·
Galderma S.A. (Nestle Skin Health S.A)
·
SkinCeuticals
·
Pierre Fabre
·
EpiPharm AG
·
RXi Pharmaceuticals Corporation
·
Obagi Cosmeceuticals LLC (Obagi medical)
·
Vivier Pharma
·
Sirona Biochem's
·
Menarini Group
About Us
Transparency Market Research is a global market intelligence company,
providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants, use proprietary data sources and various tools
and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
